Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TMDX +42.1%, DDOG +24.1%, UIS +22.5%, AYX +17.7%, VMEO +12.8%, TASK +12.5%, PAY +12.2%, PRAA +10.5%, TRIP +10.4%, ROVR +8.7%, DCGO +8.6%, RNG +8%, CELH +7.4%, CLVT +7.2%, PLNT +6.9%, HIMS +6.5% (also announced repurchase program), MTTR +6.1%, VERV +6.1%, IFF +5.6% (continuing agreement with Icahn Capital), NEO +5.1%, IMXI +5%, TWKS +4.7%, SRRK +4.7%, VECO +4.6%, SKWD +4.3%, DK +4.3%, AAON +4.1%, CBT +3.7%, HALO +3.5%, SGRY +3.3%, LEV +2.9%, SQSP +2.7%, ELAN +2.7%, IDYA +2.6%, KIDS +2.2%, UBS +2.1%, BLUE +2.1%, AMK +2%, CTRA +2%, PARR +2%, GFS +1.9%, FSK +1.8%, ATEC +1.8%, CRGY +1.8%, JELD +1.8%, STEP +1.6% (also appoints new CFO), DO +1.6%, GT +1.4%, O +1.4%
Other news:
- ADPT +6.3% (announces a multi-year global translational collaboration with BeiGene (BGNE) to assess minimal residual disease using clonoSEQ assay technology across the company's pipeline of treatments for patients with lymphoid malignancies)
- MGNX +3.3% (files mixed shelf)
- SEAT +3.2% (announces its acquisition of Vegas.com in a cash and stock transaction valued at ~$240 mln; also issues guidance)
- VLRS +2.4% (reports October capacity)
Analyst comments:
- DOCN +8% (upgraded to Buy from Sell at Goldman)
- APPN +2.9% (upgraded to Buy from Neutral at DA Davidson)
- NWG +2.6% (upgraded to Outperform from Underperform at Exane BNP Paribas)